Spots Global Cancer Trial Database for Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Official Title: Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients
Study ID: NCT05439278
Conditions
Study Description
Brief Summary: In newly diagnosed glioblastoma patients aged 70 years or older who are suitable for concurrent temozolomide, the optimal dose of radiation therapy is controversial . The purpose of this study is to compare conventional radiotherapy of 60 Gy (6 weeks) versus hypofractionated radiotherapy of 40 Gy (3 weeks) in terms of overall survival as the primary endpoint along with progression-free survival, toxicity, quality of life, and prognostic biomarkers.
Detailed Description:
Keywords
Eligibility
Minimum Age: 70 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Chan Woo Wee, MD, PhD
Affiliation: SMG-SNU Boramae Medical Center
Role: STUDY_CHAIR
Name: In Ah Kim, MD, PhD
Affiliation: Seoul National University Bundang Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
